XenoPort Trading Significantly Higher Pre-Market (XNPT)

by BenzingaStaffJ, Benzinga Staff Writer
April 7, 2011 8:26 AM | 12 seconds read |
XenoPort XNPT is trading significantly higher pre-market after receiving approval for Horizant, XNPT's drug for restless leg syndrome. At the time of posting, shares of XNPT were trading at $11.01, up 72.57% from Wednesday's close.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Intraday UpdateMoversHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!